Does Xeloda (capecitabine) cause side effects?
- cancer of the colon that has spread to lymph nodes in the area close to the colon (Dukes’ C stage) after surgery;
- cancer of the colon or rectum (colorectal) that has spread to other parts of the body (metastatic);
- breast cancer that has spread to other parts of the body (metastatic) together with another medicine called docetaxel after treatment with certain other anti-cancer medicines have not worked; and
- breast cancer that has spread to other parts of the body and has not improved after treatment with paclitaxel and certain other anti-cancer medicines, or who cannot receive any more treatment with certain anti-cancer medicines.
Xeloda is converted by the body to 5-fluorouracil (5-FU), a drug which has been given intravenously for many years to treat various types of cancer. 5-FU inhibits the production by the cancerous cells of both DNA and protein that are necessary for the cells to divide and the cancer to grow in size.
Common side effects of Xeloda include
- painful swelling of the mouth,
- painful rash and swelling of the hands or feet,
- low white blood cell count (which can lead to infections),
- low blood platelet counts (which can lead to bleeding), and
Serious side effects of Xeloda include
Drug interactions of Xeloda include blood thinner medicines, such as warfarin, because taking Xeloda with these medicines can cause changes in how fast your blood clots, and can cause life-threatening bleeding.
- This can occur as soon as a few days after you start taking Xeloda, or later during treatment, and possibly even within 1 month after you stop taking Xeloda.
- Your risk may be higher because you have cancer, and if you are over 60 years of age.
- If you take warfarin or a similar blood thinner during treatment with Xeloda, your doctor should do blood tests often, to check how fast your blood clots during and after you stop treatment with Xeloda.
- Your doctor may change your dose of the blood thinner medicine if needed.
Xeloda can damage a fetus. It should not be taken by pregnant women.
What are the important side effects of Xeloda (capecitabine)?
The most common side effects with capecitabine are:
- painful swelling of the mouth,
- painful rash and
- swelling of the hands or feet,
- low white blood cell count (which can lead to infections),
- low blood platelet counts (which can lead to bleeding), and
Other important side effects experienced by some patients include:
Xeloda (capecitabine) side effects list for healthcare professionals
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adjuvant Colon Cancer
- Table 4 shows the adverse reactions occurring in =5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.
- A total of 995 patients were treated with 1250 mg/m2 twice a day of Xeloda administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU on days 1-5 every 28 days).
- The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients.
- A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions.
- A total of 18 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to Xeloda and 10 (1.0%) randomized to 5-FU/LV.
- Table 5 shows grade 3/4 laboratory abnormalities occurring in =1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.
Table 4 Percent Incidence of Adverse Reactions Reported in =5% of Patients Treated With Xeloda or 5-FU/LV for Colon Cancer in the Adjuvant Setting (Safety Population)
|Adjuvant Treatment for Colon Cancer (N=1969)|
|Xeloda (N=995)||5-FU/LV (N=974)|
|All Grades||Grade 3/4||All Grades||Grade 3/4|
|Upper Abdominal Pain||7||<1||7||<1|
|Skin and Subcutaneous Tissue Disorders|
|General Disorders and Administration Site Conditions|
|Nervous System Disorders|
|Metabolism and Nutrition Disorders|
|Blood and Lymphatic System Disorders|
|Respiratory Thoracic and Mediastinal Disorders|
Table 5 Percent Incidence of Grade 3/4 Laboratory Abnormalities Reported in =1% of Patients Receiving Xeloda Monotherapy for Adjuvant Treatment of Colon Cancer (Safety Population)
|Advers e Event||Xeloda (n=995) Grade 3/4 %||IV 5-FU/LV (n=974) Grade 3/4 %|
|Increased ALAT (SGPT)||1.6||0.6|
|*The incidence of grade 3/4 white blood cell abnormalities was 1.3% in the Xeloda arm and 4 .9% in the IV 5-FU/LV arm. †It should be noted that grading was according to NCIC CTC Version 1 (May, 1994 ). In the NCIC-CTC Version 1, hyperbilirubinemia grade 3 indicates a bilirubin value of 1.5 to 3.0 x upper limit of normal (ULN) range, and grade 4 a value of > 3.0 x ULN. The NCI CTC Version 2 and above define a grade 3 bilirubin value of>3.0 to 10.0 x ULN, and grade 4 values >10.0 x ULN.|
Metastatic Colorectal Cancer
- Table 6 shows the adverse reactions occurring in =5% of patients from pooling the two phase 3 trials in first-line metastatic colorectal cancer.
- A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m2 twice a day of Xeloda administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1-5, every 28 days).
- In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients.
- A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LVtreated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness.
- A total of 82 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to Xeloda and 32 (5.4%) randomized to 5-FU/LV.
Table 6 Pooled Phase 3 Colorectal Trials : Percent Incidence of Adverse Reactions in =5% of Patients
|Number of Patients|
With > One Adverse
|Body System/Adverse Event|
| Gastrointestinal Motility|
| Upper GI Inflammatory|
|Skin and Subcutaneous|
|Peripheral Sensory Neuropathy||10||-||-||4||-||-|
|Blood and Lymphatic|
NA = Not Applicable
In Combination With Docetaxel
- The following data are shown for the combination study with Xeloda and docetaxel in patients with metastatic breast cancer in Table 7 and Table 8.
- In the Xeloda and docetaxel combination arm the treatment was Xeloda administered orally 1250 mg/m2 twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1- hour intravenous infusion at a dose of 75 mg/m2 on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m2 on the first day of each 3-week cycle for at least 6 weeks.
- The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm.
- A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions.
- The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm.
- The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%.
- Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.
Table 7 Percent Incidence of Adverse Events Considered Related or Unrelated to Treatment in =5% of Patients Participating in the Xeloda and Docetaxel Combination vs Docetaxel Monotherapy Study
|Adverse Event||Xeloda 1250|
mg/m2 /bid With
75 mg/m2 /3 weeks (n=251)
100 mg/m2 /3 weeks (n=255)
|Number of Patients|
With at Least One
|Body System/Adverse Event|
|Skin and Subcutaneous|
|Pain in Limb||13||<1||-||13||2||-|
|Chest Pain (non-cardiac)||4||<1||-||6||2||-|
|Urinary Tract Infection||6||<1||-||4||-||-|
|Upper Respiratory Tract||4||-||-||5||1||-|
NA = Not Applicable
Table 8 Percent of Patients With Laboratory Abnormalities Participating in the Xeloda and Docetaxel Combination vs Docetaxel Monotherapy Study
|Adverse Event||Xeloda 1250 mg/m2 /bid With|
Docetaxel 75 mg/m2 /3 weeks
|Docetaxel 100 mg/m2 /3 weeks|
- The following data are shown for the study in stage IV breast cancer patients who received a dose of 1250 mg/m2 administered twice daily for 2 weeks followed by a 1-week rest period.
- The mean duration of treatment was 114 days.
- A total of 13 out of 162 patients (8%) discontinued treatment because of adverse reactions/intercurrent illness.
Table 9 Percent Incidence of Adverse Reactions Considered Remotely, Possibly or Probably Related to Treatment in =5% of Patients Participating in the Single Arm Trial in Stage IV Breast Cancer
|Adverse Event||Phase 2 Trial in Stage IV Breast|
|Body System/ Adverse Event||Total|
|Skin and Subcutaneous|
|Pain in Limb||6||1||-|
|– Not observed|
NA = Not Applicable
Clinically Relevant Adverse Events In <5% Of Patients
- Clinically relevant adverse events reported in <5% of patients treated with Xeloda either as monotherapy or in combination with docetaxel that were considered at least remotely related to treatment are shown below; occurrences of each grade 3 and 4 adverse event are provided in parentheses.
Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)
|Gastrointestinal:||abdominal distension, dysphagia, proctalgia, ascites (0.1%), gastric ulcer (0.1%), ileus (0.3%), toxic dilation of intestine, gastroenteritis (0.1%)|
|Skin & Subcutan.:||nail disorder (0.1%), sweating increased (0.1%), photosensitivity reaction (0.1%), skin ulceration, pruritus, radiation recall syndrome (0.2%)|
|General:||chest pain (0.2%), influenza-like illness, hot flushes, pain (0.1%), hoarseness, irritability, difficulty in walking, thirst, chest mass, collapse, fibrosis (0.1%), hemorrhage, edema, sedation|
|Neurological:||insomnia, ataxia (0.5%), tremor, dysphasia, encephalopathy (0.1%), abnormal coordination, dysarthria, loss of consciousness (0.2%), impaired balance|
|Metabolism:||increased weight, cachexia (0.4%), hypertriglyceridemia (0.1%), hypokalemia, hypomagnesemia|
|Respiratory:||cough (0.1%), epistaxis (0.1%), asthma (0.2%), hemoptysis, respiratory distress (0.1%), dyspnea|
|Cardiac:||tachycardia (0.1%), bradycardia, atrial fibrillation, ventricular extrasystoles, extrasystoles, myocarditis (0.1%), pericardial effusion|
|Infections:||laryngitis (1.0%), bronchitis (0.2%), pneumonia (0.2%), bronchopneumonia (0.2%), keratoconjunctivitis, sepsis (0.3%), fungal|
infections (including candidiasis) (0.2%)
|Musculoskeletal:||myalgia, bone pain (0.1%), arthritis (0.1%), muscle weakness|
|Blood & Lymphatic:||leukopenia (0.2%), coagulation disorder (0.1%), bone marrow depression (0.1%), idiopathic thrombocytopenia purpura (1.0%), pancytopenia (0.1%)|
|Vascular:||hypotension (0.2%), hypertension (0.1%), lymphoedema (0.1%), pulmonary embolism (0.2%), cerebrovascular accident (0.1%)|
|Psychiatric:||depression, confusion (0.1%)|
|Renal:||renal impairment (0.6%)|
|Hepatobiliary:||hepatic fibrosis (0.1%), hepatitis (0.1%), cholestatic hepatitis (0.1%), abnormal liver function tests|
|Immune System:||drug hypersensitivity (0.1%)|
|Postmarketing:||hepatic failure, lacrimal duct stenosis, acute renal failure secondary to dehydration including fatal outcome [see WARNINGS AND PRECAUTIONS], cutaneous lupus erythematosus, corneal disorders including keratitis, toxic leukoencephalopathy, severe skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (TEN) [see WARNINGS AND PRECAUTIONS]|
Xeloda In Combination With Docetaxel (Metastatic Breast Cancer)
|Gastrointestinal:||ileus (0.4%), necrotizing enterocolitis (0.4%), esophageal ulcer (0.4%), hemorrhagic diarrhea (0.8%)|
|Neurological:||ataxia (0.4%), syncope (1.2%), taste loss (0.8%), polyneuropathy (0.4%), migraine (0.4%)|
|Cardiac:||supraventricular tachycardia (0.4%)|
|Infection:||neutropenic sepsis (2.4%), sepsis (0.4%), bronchopneumonia (0.4%)|
|Blood & Lymphatic:||agranulocytosis (0.4%), prothrombin decreased (0.4%)|
|Vascular:||hypotension (1.2%), venous phlebitis and thrombophlebitis (0.4%), postural hypotension (0.8%)|
|Renal:||renal failure (0.4%)|
|Hepatobiliary:||jaundice (0.4%), abnormal liver function tests (0.4%), hepatic failure (0.4%), hepatic coma (0.4%), hepatotoxicity (0.4%)|
|Immune System:||hypersensitivity (1.2%)|
What drugs interact with Xeloda (capecitabine)?
- Altered coagulation parameters and/or bleeding have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
- These events occurred within several days and up to several months after initiating Xeloda therapy and, in a few cases, within 1 month after stopping Xeloda.
- These events occurred in patients with and without liver metastases.
- In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin.
- The maximum observed INR value increased by 91%.
- This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites.
- The level of phenytoin should be carefully monitored in patients taking Xeloda and phenytoin dose may need to be reduced.
- Postmarketing reports indicate that some patients receiving Xeloda and phenytoin had toxicity associated with elevated phenytoin levels.
- Formal drug-drug interaction studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme by capecitabine and/or its metabolites.
- The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
- Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
- Other than warfarin, no formal drug-drug interaction studies between Xeloda and other CYP2C9 substrates have been conducted.
- Care should be exercised when Xeloda is coadministered with CYP2C9 substrates.
- Food was shown to reduce both the rate and extent of absorption of capecitabine. In all clinical trials, patients were instructed to administer Xeloda within 30 minutes after a meal. It is recommended that Xeloda be administered with food.
Xeloda (capecitabine) is an antineoplastic (anti-cancer) medication used to treat breast cancer and cancer of the colon or rectum (colorectal). Common side effects of Xeloda include diarrhea, nausea, vomiting, painful swelling of the mouth, fatigue, painful rash and swelling of the hands or feet, low white blood cell count (which can lead to infections), low blood platelet counts (which can lead to bleeding), and anemia. Xeloda can damage a fetus. It should not be taken by pregnant women. It is unknown if Xeloda is secreted into breast milk.
Multimedia: Slideshows, Images & Quizzes
Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment
Learn about breast cancer causes, symptoms, tests, recovery, and prevention. Discover the types of treatments such as surgery and...
Colorectal Cancer: Symptoms, Signs, Screening, Stages
Colorectal cancer (colon cancer) is the cause of many cancer deaths. Learn about the warning signs, symptoms, screening process,...
Colon Cancer: How Your Diet Can Affect Colorectal Cancer
Diet, including nutrient, antioxidant, and vitamin intake, affects colon cancer risk. Certain dietary factors either decrease or...
10 Things Young Women Should Know About Breast Cancer
Is breast cancer genetic? Should I get tested for the BRCA gene? What every young women should know about breast cancer. Discover...
Breast Cancer: Visual Guide to Male Breast Cancer
Breast cancer isn't just a woman's disease. Learn about the symptoms and treatment of male breast cancer, and find out what can...
Breast Cancer Quiz: Symptoms & Signs
This Breast Cancer Quiz features signs, symptoms, facts, causes, common forms, terms, risk factors, statistics, and more. ...
Breast Cancer: Where It Can Spread
When breast cancer spreads, or metastasizes, it often goes to these five places: the lymph nodes, bones, liver, lungs, and brain....
Picture of Colon Cancer
Most, if not all, of these cancers develop from colonic polyps. Removal of these precancerous polyps can prevent colon cancer....
Breast Cancer: Diet Tips for Breast Cancer
No single food or diet plan prevents breast cancer, but what you eat plays a role in how likely you are to get the disease or...
Related Disease Conditions
Early Warning Signs and Stages of Colon Cancer
Colon cancer usually does not cause signs or symptoms in the early stages. As the cancer grows, signs may include blood in the stool, bowel habit changes, abdominal pain, and fatigue. Learn about stages and treatment of colon cancer.
Colon Cancer (Colorectal Cancer)
Colon Cancer (Colorectal Cancer) is a malignancy that arises from the inner lining of the colon. Most, if not all, of these cancers, develop from colonic polyps. Removal of these precancerous polyps can prevent colon cancer.
Second Source article from Government
Breast Cancer in Men
Second Source WebMD Medical Reference
Early Signs of Colon Cancer
Colon or colorectal cancer may not cause any symptoms during the early stages of the disease. A person may have polyps or colon cancer but may not have any symptoms till the late stages of the disease.
Male Breast Cancer
Male breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.
Triple-Negative Breast Cancer
Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.
What Is Usually the First Sign of Breast Cancer?
A lump in the breast or in the armpits is often the first sign of breast cancer. This may be felt while in the shower. There may or may not be changes in the structure of the breast. Other early signs include changes in breast skin, breast pain and others.
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors. What you should know about breast cancer Breast cancer is the most common cancer among American women.One in every eight women in the United States develops breast cancer.There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues.The causes of breast cancer are unknown, although medical professionals have identified a number of risk factors.There are many different types of breast cancer.Breast cancer symptoms and signs includea lump in the breast or armpit,bloody nipple discharge,inverted nipple,orange-peel texture or dimpling of the breast's skin (peau d'orange),breast pain or sore nipple,swollen lymph nodes in the neck or armpit, anda change in the size or shape of the breast or nipple.Breast cancer can also be symptom free, which makes following national screening recommendations an important practice.Breast cancer is diagnosed during a physical exam, by a self-exam of the breasts, mammography, ultrasound testing, and biopsy.Treatment of breast cancer depends on the type of cancer and its stage (0-IV) and may involve surgery, radiation, or chemotherapy.
Inflammatory Breast Cancer
Inflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
Can Fibroadenomas Turn Into Breast Cancer?
A fibroadenoma is the most common type of benign, non-cancerous lump of the breast. Although it is rare, complex fibroadenomas and phyllodes tumors have a chance to develop into malignant breast cancer.
Breast Cancer Prevention
Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.
Breast Cancer Stages
Breast cancer staging is the determination of the extent and spread of the cancer. An individual's health care team uses stages to summarize the extent of the cancer in a standardized way that is recognized by all health care providers. They use this staging to determine the treatment most appropriate for the type of cancer. Cancer staging helps to determine the prognosis, or outlook, of a cancer, including rates of recurrence and survival rates.
How Long After Breast Cancer Can You Get Lymphedema?
Breast cancer means a disease in which the cells of your breast abnormally grow out of control. It commonly occurs in women than in men. There are different types of breast cancer depending on the type of cells that turned cancerous (grow wildly).
Breast Cancer Treatment
Breast cancer treatments depend upon the type of breast cancer that is present as well as the stage (extent of spread) of the tumor. Treatment for early breast cancer typically involves surgery to remove the tumor. After surgery, medical professionals may administer radiation therapy, chemotherapy, or targeted therapy.
What Are The Five Warning Signs Of Breast Cancer?
The majority of breast cancer patients first seek diagnosis because of a lump on the breast. This is one of the five warning signs of breast cancer. Others include changes in the nipple, changes in the breast skin and other symptoms.
Breast Cancer Facts
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
Breast Cancer Symptoms and Signs
In most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
Breast Cancer and Lymphedema
Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.
What Are the Four Types of Breast Cancer?
The four most common types of breast cancer are ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma. The designations are based on the locations of the tumors, whether they have spread and where they have spread to.
Breast Cancer Recurrence
Breast cancer most often recurs within the first three to five years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Treatment for recurrent breast cancer depends on the initial treatment.
Eight Early Signs of Breast Cancer
Breast cancer is the second most common cancer affecting women in the United States (next to some types of skin cancer that are most common). Screening tests can help you identify if you have the condition.
HER2-Positive Breast Cancer
In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative. Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
Colon Cancer Prevention
Colorectal cancer is both curable and preventable if it is detected early and completely removed before the cancerous cells metastasize to other parts of the body. Colonoscopy and flexible sigmoidoscopy (along with digital rectal examination and stool occult blood testing) are both effective at preventing colo-rectal cancers and detecting early colo-rectal cancers.
What Is the BRCA Gene?
BRCA genes (BRCA 1 and 2, when normal, repair damaged DNA) are among the genetic mutations linked to breast cancer, ovarian cancer, and other cancers when mutated. Every woman with a BRCA mutation is at high risk for breast cancer, irrespective of whether she has a family history of breast cancer or not. By age 80, a woman with a BRCA mutation has about an 80% chance of developing breast cancer. BRCA1 and BRCA2 gene mutations also increase the risk of ovarian cancer, by 54% and 23%, respectively.
Breast Cancer Growth Rate
The available evidence suggests that breast cancer may begin to grow around 10 years before it is detected. However, the time for development differs from tumor to tumor.
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include: hormone therapy, radiation therapy, surgery, chemotherapy, HER2-targeted therapy, neoadjuvant therapy, and adjuvant therapy.
Breast Cancer in Young Women
About 5% of cases of breast cancer occur in women under the age of 40 years old. Some risk factors for breast cancer in young women include a personal history of breast cancer or breast disease, family history of breast cancer, prior radiation therapy, and the presence of BRCA1/BRCA2 gene mutations. Breast self-exams, clinical breast exams, and screening mammograms may help detect breast cancer. Treatment may include surgery, chemotherapy, radiation, and hormone therapy.
What Questions Should I Ask My Doctor About Breast Cancer?
A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.
Breast Cancer During Pregnancy
Breast cancer occurs in about 1 in every 1,000 pregnant women. Treatment of breast cancer during pregnancy involves surgery, but it is very difficult to protect the baby from the dangerous effects of radiation and chemotherapy. It can be an agonizing to decide whether or not to undergo breast cancer treatment while one is pregnant.
What Is the Newest Treatment for Breast Cancer?
Targeted therapies are a newer form of breast cancer treatment. They can be used alone or along with other therapies. Targeted therapies directly target cancer cells or specific processes that contribute to the growth of cancer cells. Target therapy often has fewer side effects.
Breast Cancer and Coping With Stress
Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.
Breast Cancer Clinical Trials
Breast cancer clinical trials are research programs designed to evaluate new medical treatments, drugs, or devices for the treatment of breast cancer. Clinical trials are designed to test the safety and efficacy of new treatments as well as assess potential side effects. Clinical trials also compare new treatment to existing treatments to determine if it's any better. There are many important questions to ask your doctor before taking part in a breast cancer clinical trial.
How Can You Detect Breast Cancer Early?
Breast cancer develops from the cells of the breasts and can spread to other parts of the body (metastasis). It is one of the most common cancers diagnosed in women in the United States. A lump in the breast or armpit is often the first sign. Treatment success depends largely on early detection.
Estimating Breast Cancer Risk: Questions and Answers
As breast cancer is the most diagnosed non-skin cancer in American women, it is important to know your breast cancer risk. Risk factors include age, age at menarche, age at first live birth, history of breast abnormalities, breast biopsies, race, and history or breast cancer among first-degree relatives.
Genetic Testing: Families With Breast Cancer
Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Are There Any Clinical Trials for Breast Cancer?
Breast cancer is the second most common cancer among American women. Around 250,000 women and 2,300 men are diagnosed with breast cancer each year in the United States. Each year, breast cancer kills around 42000 women and 510 men in the United States.
Treatment & Diagnosis
- Colon Cancer
- Breast Cancer Husband
- Breast Cancer
- Inflammatory Breast Cancer
- Breast Cancer
- Breast Cancer: A Feisty Women's Discussion
- Colon Cancer Update
- Breast Cancer, Metastatic: Treatment Goals and Therapy Options -- Harold J. Burstein, MD
- Colon Cancer Update: James Church, MD
- Breast Cancer Treatment Update
- Colon Cancer Update with The Cleveland Clinic
- Breast Cancer FAQs
- Stage IV Colon Cancer That Has Spread to the Liver
- Colon Cancer Prevention And Fiber?
- Colon Cancer and Polyp Screening Guidelines
- Colon Cancer Silences Howard Keel
- Colon Cancer, The Genetic Factor
- How Long Do You Live After Being Diagnosed with Colon Cancer?
- What Are the Early Signs of Colon Cancer?
- What Is the Best Way to Prevent Colon Cancer?
- What Is the Survival Rate for Colon Cancer?
- How Common and Dangerous Is Male Breast Cancer?
- How Many Breast Cancer Deaths Are there Each Year?
- Where Can Breast Cancer Spread To?
- Why Is Breast Cancer More Common in Females than Males?
- How Much Breast Cancer is Genetic?
- How Long Can Breast Cancer Patients Live?
- Who Does Breast Cancer Affect?
- How Does Breast Cancer Form?
- How Many Breast Cancer Stages Are There?
- How Does Colon Cancer Affect a Person's Body?
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.